Evrysdi® Start Form

www.evrysdi.com/forms | Phone: (833) 387-9734 | Fax: (833) 387-9700

M-US-00001154(v5.0)

Instructions for Patients

By completing this form, you can:



Learn about your health insurance coverage and financial assistance options through Genentech MySMA Support[™].



Sign up to receive **optional** disease education and other material, including **optional** services from Genentech MySMA Support.

You can choose not to sign this form. However, Genentech cannot provide you with your insurance benefits investigation and other financial assistance options without your signed authorization on page 4. Enrollment in this program does not impact your ability to gain access to Evrysdi from your health care provider or health plan.

■ Please follow these steps to get started:

- **Read** the "Authorization to Use and Disclose Personal Information" section on page 3.
- **Complete, sign and date** page 4 of the Evrysdi Start Form. Please note you must sign the form to get support for your treatment.
- **Send** in your completed form using one of the options below.

Genentech can start supporting you when **page 4** of this form is submitted by you or your doctor's office in one of the following ways:



Complete online by scanning this QR code or visiting www.evrysdi.com/forms





Take a photo and text it to (650) 877-1111





Print, complete and fax it to (833) 387-9700

Please write legibly and complete all required fields (*) on the Evrysdi Start Form to avoid any delays.

Please note: Your doctor has to complete the Evrysdi Prescriber Service Form before we can begin helping you.

If you have any questions, talk to your health care provider or call (833) 387-9734.

Evrysdi® Start Form

www.evrysdi.com/forms | Phone: (833) 387-9734 | Fax: (833) 387-9700

M-US-00001154(v5.0)

Helpful Terminology

Genentech: The maker of the medicine your doctor wants to prescribe for you. Genentech is committed to helping patients get the medicine their doctor prescribed. When used on this form, "Genentech" refers to Genentech, Genentech Patient Foundation, and their respective partners, affiliates, subcontractors and agents.

MySMA Support™: Your support team at Genentech that works with your doctor and your health insurance plan to help you get your prescribed Evrysdi medicine. The Genentech MySMA team includes your Case Manager (CM) and specialty pharmacy (SP). If you sign up for **optional** services and materials, it also includes a Partnership and Access Liaison (PAL). **Optional** services from MySMA Support can also provide disease education and relevant resources.

Partnership and Access Liaison (PAL): An optional local point of contact from Genentech who supports people taking Evrysdi. PALs are here to answer questions about Evrysdi, refer you to helpful resources and help you understand your insurance and financial support options. A PAL is not part of your medical team and is not a substitute for your health care provider. PALs do not provide medical advice. Your health care provider should always be your main resource for any questions about your health and medical care.

Case Manager (CM): The Genentech representative that partners closely with your health care provider, and if you choose, the PAL, to help you understand your health insurance coverage and potential financial support options for Evrysdi.

Specialty pharmacy (SP): Specialty pharmacies manage drugs that need special handling or storage, such as Evrysdi. The SP will directly ship Evrysdi to you. Prior to shipping your monthly Evrysdi, the SP will call to confirm your address and other logistics. It is very important you answer its call to avoid any delays in receiving your treatment.

Genentech Patient Foundation: A program that gives free Genentech medicine to eligible people who don't have insurance coverage or who have financial concerns.

Household size: Number of people living in your household, including you.

Annual household income: How much you and the members of your household make each year, minus specific deductions. This is also frequently referred to as your adjusted gross income or AGI. This information is needed to determine Genentech Patient Foundation eligibility.

Deductible: The amount you pay for your health care services or medicines before your health insurance plan begins to pay.

Out-of-pocket costs: The amount not paid by your insurance plan that you must pay for your treatment. This includes deductibles, co-pays and co-insurance.

Co-pay assistance: Programs available to help eligible patients pay for their medicines.

Alternate contact: Someone you choose to be your contact person if Genentech MySMA Support cannot reach you.

Legally authorized representative: An individual or judicial or other body authorized under applicable law to consent on behalf of a patient (e.g., parent or legal guardian of a minor).

Terms and Conditions of the Genentech Patient Foundation

- If I receive free medicine from the Genentech Patient Foundation, I will not sell or give out the
 medicine because it is illegal to do so. I am responsible to ensure that the medicine is sent to a
 secure address when shipped to me, and I must control any medicine that I receive
- I understand that, for purposes of an audit, the Genentech Patient Foundation could ask me for a copy of my IRS 1040 form or other proof of income

Evrysdi® Start Form

www.evrysdi.com/forms | Phone: (833) 387-9734 | Fax: (833) 387-9700

M-US-00001154(v5.0)

Authorization to Use and Disclose Personal Information

I authorize my physician(s) and their staff, pharmacies, and health insurance plan (my "health care providers") to share my personal information, which may include contact information, demographic information, financial information, and information related to my medical condition, treatments, and health insurance and benefits, with Genentech, Genentech Patient Foundation, and their respective partners, affiliates, subcontractors, and agents (together, "Genentech"). I authorize Genentech to receive, use, and share my personal information in order to provide me with access to the products, services, and programs described on this form, which may include the following:

- Working with my health insurance plan to understand or verify coverage for Genentech products
- Applying to the Genentech Patient Foundation
- Determining my eligibility for and facilitating enrollment into financial assistance services if I'm eligible, including co-pay assistance
- Coordinating my prescription through a pharmacy, infusion site and/or health care provider's office. This
 includes contacting me to discuss my coverage, costs and eligibility for assistance and other program
 administration purposes
- Facilitating my access to Genentech products
- Ensuring quality and safety and improving our products and services
- Contacting me by mail, e-mail, telephone calls and text messages at the number(s) and address(es) provided for non-marketing purposes
- If I agree to the **optional** Consent for Patient Resources and Information, providing me with **optional** disease information and marketing material about products, services and programs offered by Genentech, its partners and their respective affiliates. This includes **optional** services or engagement from Genentech MySMA Support, which may include outreach by a PAL. This is not required to receive help from Genentech MySMA Support with understanding health insurance coverage and potential financial support programs
- If I agree to the **optional** Telephone Consumer Protection Act (TCPA) Consent, contacting me by autodialed calls and/or text messages at the phone number(s) I have provided for marketing purposes, including text messages from a PAL. This is not required to receive help from Genentech MySMA Support with understanding health insurance coverage and potential financial support programs

I understand that Genentech may also share my personal information for the purposes described on this authorization with my health care providers, service providers, and any individual I may designate as an alternate contact. I understand that my pharmacy may receive payment or other remuneration for disclosing my personal information pursuant to this authorization. I can choose not to sign this authorization, but Genentech will not be able to provide the services to me without it. However, my health care providers may not condition either my treatment or my payment, enrollment, or eligibility for benefits on signing this authorization.

I also understand and agree that:

- This authorization is valid for 6 years from the date I sign or the date I last enrolled, whichever comes first, unless a shorter period is required by law, or I revoke it earlier
- My personal information released under this authorization may no longer be protected by state and federal law, including the Health Insurance Portability and Accountability Act (HIPAA). However, Genentech will only use and share my personal information for the purposes stated on this authorization or as otherwise permitted by law
- I have the right to revoke (cancel) this authorization at any time by submitting a written notice to: Genentech Access Solutions, 1 DNA Way, South San Francisco, CA 94080-4990. If I revoke this authorization, I will no longer be eligible for the services described. If a health care provider is disclosing my personal information to Genentech on an authorized, ongoing basis, my revocation will be effective with respect to such health care provider when they receive notice of my revocation. My revocation will not impact uses and disclosures of my personal information that have already occurred in reliance on this authorization
- More information on my privacy rights, including specific rights I may have as a resident of certain states, like California, can be found in Genentech's privacy policy (www.gene.com/privacy-policy)
- I have a right to receive a copy of this authorization

Evrysdi® Start Form risdiplam

www.evrysdi.com/forms | Phone: (833) 387-9734 | Fax: (833) 387-9700

*Required field M-US-00001154(v5.0)

Pal	tient Information (to be completed by patient or their legally authorized representative)						
*First name:*Last name:							
Hom	e phone: () Cell phone: ()						
OK to leave a detailed message? Date of birth (MM/DD/YYYY):/							
Emai	Email: Preferred language: English Spanish Other:						
Alternate Contact (OPTIONAL) Full name:							
Relat	Relationship: Phone: ()						
1	Financial Eligibility: Complete only if you are applying to the Genentech Patient Foundation By completing this section, I am agreeing to the Terms and Conditions of the Genentech Patient Foundation outlined on page 2. Household size (including you): Annual household income: Under \$75,000 \$75,000 - \$100,000 \$100,001 - \$125,000 \$125,001 - \$150,000 Over \$150,000						
2	Consent for Patient Resources and Information (OPTIONAL) Genentech offers optional and free disease education and other material for patients. This includes optional services or engagement from MySMA Support™, which may include outreach by a PAL. This may include information and marketing material about products, services and programs offered by Genentech, its partners and their respective affiliates. If you sign up, you will be contacted using the information you have provided. By checking this box, I agree to receive optional disease education and other material. This includes optional services or engagement from Genentech MySMA Support, which may include outreach by a PAL. I understand that I do not have to check this box to get my medicine or to get Genentech support with understanding my health insurance coverage and potential financial support programs. I also understand that I may opt out of receiving this information at any time by calling (877) 436-3683 and this consent will remain active unless I opt out. Telephone Consumer Protection Act (TCPA) Consent (OPTIONAL) By checking this box, I consent to receive autodialed marketing calls and text messages from and on behalf of Genentech at the phone number(s) I have provided, including text messages from a PAL. I understand that consent is not a requirement of any purchase or enrollment. Message frequency may vary. Message and data rates may apply. I may opt out at any time by texting STOP or calling (877) GENENTECH/(877) 436-3683.						
REQUIRED ¹⁰	By signing this form, I acknowledge that I have provided accurate and complete information and understand and agree to the terms of this form. My signature certifies that I have read, understood, and agree to the release and use of my personal information pursuant to the Authorization to Use and Disclose Personal Information and as otherwise stated on this form. Sign and date here *Signature of Patient/Legally Authorized Representative (A parent or guardian must sign for patients under 18 years of age) (MM/DD/YYYY)						
RE	(if not patient) Print first name Print last name Relationship to nationt						
Onco	Print first name Print last name Relationship to patient this page (4/6) has been completed, please text a photo of the page to (650) 877-1111 or fax						

to (833) 387-9700. You can also complete this form online at www.evrysdi.com/forms.

If this is an electronic consent, you understand that by typing your name and the date above and submitting, or taking a picture and sending to us, that you are providing your consent electronically and that it has the same force and effect as if you were signing in person on paper. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Page 4 of 6

Evrysdi® Start Form

www.evrysdi.com/forms | Phone: (833) 387-9734 | Fax: (833) 387-9700

M-US-00001154(v5.0)

Instructions for Health Care Providers

By completing this form, you are requesting services on behalf of your patient, which may include:



Insurance benefits investigation



Resources for prior authorizations and appeals



Referral of eligible patients to co-pay support options or the Genentech Patient Foundation

To enroll your patient, please follow these steps:

- 1 Have your patient read pages 2 and 3.
- 2 Have your patient complete the Patient Information on page 4 and sign and date Section 3:
 - Only the Patient Information and Section 3 are required for insurance coverage and financial assistance options support
 - If your patient is requesting free medicine from the Genentech Patient Foundation, they should also complete Section 1
 - If your patient is requesting optional disease education and other material, including optional services from Genentech MySMA Support[™], they should also complete Section 2
- **3** Complete page 6 and sign and date the Health Care Provider Certification.
- **Submit pages 4 and 6 of the Start Form** via fax to (833) 387-9700 or eSubmit at www.evrysdi.com/forms. Page 4 of the Start Form can also be submitted by text to (650) 877-1111 as indicated on page 1.

Please write legibly and complete all required fields (*) on the Evrysdi Start Form to avoid any delays.

Evrysdi® Start Form risdiplam

www.evrysdi.com/forms \mid **Phone:** (833) 387-9734 \mid **Fax:** (833) 387-9700

*Required field M-US-00001154(v5.0)

Prescriber Service	Form — To be completed b	by the pres	scriber			
Step 1 Patient In	formation					
First name:	*Last name:			Gen	der: Male	Female
Date of birth (MM/DD/YYYY):	// Preferred language:	English S	panish Other:			
Street:	Apt: (City:		*State:	ZIP:	
	Cell phone: ()			contact patient		
Alternate contact name:	Relations	ship:	Alt	phone: (_)	
Step 2 Insurance	Information					
s the patient insured? Yes	No					
•	mation below or attach a copy of the p	atient's medica	al and prescription ins	urance cards.		
	Primary Insurance	Seco	ndary Insurance	Pha	armacy Benefit	
Insurance name						
Subscriber name (if not patient)						
Subscriber/Policy ID #						
Group #						
Insurance phone						
Step 3 Diagnosis	and Clinical Information					
	antile spinal muscular atrophy type 1	G12 1 Other	inherited spinal musci	ılar atrophy		
	nal muscular atrophy, unspecified		innented spinal muset			
<u> </u>	4 SMN2 copy number: F					/
				Date medeal	<u></u>	
	S No Expected Evrysdi treatment st				-1 /	,
• • • •	usinersen) last dose://	_	ia® (onasemnogene abep			
		Drug and non-o	drug allergies:		NO KNOW	n allergies
Step 4 Prescription				_		
Strength	Directions		Route	Qu	antity	Refills
Evrysdi® (risdiplam)	mg (mL) once daily	Oral		1-ma	onth supply	
0.75 mg/mL 80 mL (in 100 mL bottle	5 mg (6.6 mL) once daily SIG:		ling tube	Othe	er:	
Your signature authorizes the specialty pharm	nacy to dispense needed ancillary supplies for enteral adm			s oral syringes casset	tes administrations	ets and tubing
	r Information	illinistration of this med	ication, sacrias. Erri it adapter	o, orai syringes, easset	ics, administrations	cts and tabing.
•	*Last name:		*Practice n	mo		
	Last name: *					
	Suite Prescriber NPI [†] #: _					
	Contact phone: (
			- Cont			
Sten 6 Fyrysdi St			Cont	act lax. (
	art Program (Signature Required)		Cont	act lax. (
Dispense: 1-shipment supply.	art Program (Signature Required)		For full eligib	oility criteria, ple		your
Step 6 Evrysdi St Dispense: 1-shipment supply mg (mL) once daily 1-time refill. Weight-based dos	or 5 mg (6.6 mL) once daily			oility criteria, ple		your
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos	or 5 mg (6.6 mL) once daily		For full eligik Evrysdi repro	oility criteria, ple esentative.	ease speak to	
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty pharr Step 7 Health Ca	ort Program (Signature Required) OR 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adr re Provider Certification	ministration of this med	For full eligit Evrysdi repro dication, such as: ENFit® adapte	oility criteria, ple esentative. rs, oral syringes, casset	ease speak to	sets and tubing.
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty pharr Step 7 Health Ca By submitting this form, I certify: (a) The above therapy In the FDA-approved label, I am prescribing the medica	or Program (Signature Required) OR 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adrese Provider Certification vis medically necessary for this patient and the treatment decision tion for an "unapproved" use, meaning that the FDA has not approved use, meaning that the FDA has not approved to the read that the read	ministration of this med n has been made by the proved the efficacy, dosage	For full eligit Evrysdi reprodication, such as: ENFit® adapte rescribing physician. (b) If the indicat amount or safety of this medication f	cility criteria, ple esentative. rs, oral syringes, casset ion for which I am prescrib or such a use. (c) I received	ease speak to	sets and tubing.
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty pharr Step 7 Health Ca By submitting this form, I certify: (a) The above therapy In the FDA-approved label, I am prescribing the medica information above and other protected health informaticontractors for the purpose of requesting reimburseme	or 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adr re Provider Certification vis medically necessary for this patient and the treatment decision tion for an "unapproved" use, meaning that the FDA has not appro on (as defined by the Health Insurance Portability and Accountab nt support, assisting in initiating or continuing therapy, as a break	ministration of this med n has been made by the proved the efficacy, dosage illity Act of 1996 [HIPAA]) in treatment would negati	For full eligit Evrysdi reprodication, such as: ENFit® adapte rescribing physician. (b) If the indicat amount or safety of this medication to Genentech, Inc., Generbech Accevely impact the patient's therapeutic	pility criteria, ple esentative. rs, oral syringes, casset ion for which I am prescrib or such a use. (e) I receive ss Solutions, the contracte outcome and (d) I will not	ease speak to tes, administrations ing a Genentech produ the authorization to re dispensing pharmac attempt to seek reimbi	sets and tubing. ct is not listed elease the y, or other arsement for free
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty pharr Step 7 Health Ca By submitting this form, I certify: (a) The above therapy in the FDA-approved label, I am prescribing the medica information above and other protected health informati contractors for the purpose of requesting reimburseme oroduct provided to the patient. I request Genentech Ac investigation (BI), prior authorization support (PA), cc.p-	or 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adr re Provider Certification vis medically necessary for this patient and the treatment decision tion for an "unapproved" use, meaning that the FDA has not approon (as defined by the Health Insurance Portability and Accountab nt support, assisting in initiating or continuing therapy, as a break ocess Solutions convey to the pharmacy chosen by the above-name ay card and co-pay assistance foundation referral. (f) No action of the control of the con	ministration of this med n has been made by the proved the efficacy, dosage wilthy Act of 1996 [HIPAA]) in treatment would negatined patient the prescription these services will be ta	For full eligit Evrysdi reprodication, such as: ENFit® adapte rescribing physician. (b) If the indicat amount or safety of this medication for the Genentech, Inc., Genentech Acce wely impact the patient's therapeutic on described herein. (e) The services ken until the patient consent docume	pility criteria, pleesentative. rs, oral syringes, casset ion for which I am prescrib or such a use. (c) I received ss Solutions, the contracte outcome and (d) I will not you are requesting on beh ent has been received. (g)	ease speak to tes, administration ing a Genentech produ If the authorization to re d dispensing pharmac attempt to seek reimb aff of the patient, may i	ct is not listed elease the y, or other ursement for free notlude benefits ly with all state-
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty phare Step 7 Health Ca By submitting this form, I certify: (a) The above therapy in the FDA-approved label, I am prescribing the medica information above and other protected health informati contractors for the purpose of requesting reimburseme product provided to the patient. I request Genentech Ac investigation (BI), prior authorization support (PA), co-p specific prescription requirements, such as e-prescribi Patient Foundation (GPF). (0) I understand that Genente	or 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adr re Provider Certification vis medically necessary for this patient and the treatment decision tion for an "unapproved" use, meaning that the FDA has not appro on (as defined by the Health Insurance Portability and Accountab int support, assisting in initiating or continuing therapy, as a break cosess Solutions convey to the pharmacy chosen by the above-nam aya card and co-pay assistance foundation referral. (f) No action on ray, state-specific prescription form, fax language, etc. Noncomplich reserves the right to modify or discontinue the program at any	ministration of this med n has been made by the proved the efficacy, dosage ilitity Act of 1996 [HIPAA]) in treatment would negatined patient the prescription in these services will be ta iance with state-specific r time and to verify the acc	For full eligit Evrysdi reprodication, such as: ENFit® adapte rescribing physician. (b) If the indicat amount or safety of this medication to Genentech, Inc., Genentech Accevely impact the patient's therapeutic on described herein. (e) The services ken until the patient consent docume quirements could result in outreach uracy of information submitted. (f) I ure acceptance of the country of the	polity criteria, ple esentative. In the property of the prope	ease speak to tes, administration: ing a Genentech product the authorization to red dispensing pharmac attempt to seek reimble alf of the patient, may increase must compratient meets the criter see not provide free dru	ct is not listed elease the y, or other ursement for free nclude benefits ly with all state- a for Genentecking in the instance
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty phare Step 7 Health Ca By submitting this form, I certify: (a) The above therapy in the FDA-approved label, I am prescribing the medica information above and other protected health informati contractors for the purpose of requesting reimburseme product provided to the patient. I request Genentech Ac investigation (BI), prior authorization support (PA), co-p specific prescription requirements, such as e-prescribi Patient Foundation (GPF). (0) I understand that Genente	or 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adr re Provider Certification vis medically necessary for this patient and the treatment decision tion for an "unapproved" use, meaning that the FDA has not appro on (as define by the Health Insurance Portability and Accountab nt support, assisting in initiating or continuing therapy, as a break coess Solutions convey to the pharmacy chosen by the above-nam any card and co-pay assistance foundation referral. (f) No action on ng, state-specific prescription form, fax language, etc. Noncompli	ministration of this med n has been made by the proved the efficacy, dosage ilitity Act of 1996 [HIPAA]) in treatment would negatined patient the prescription in these services will be ta iance with state-specific r time and to verify the acc	For full eligit Evrysdi reprodication, such as: ENFit® adapte rescribing physician. (b) If the indicat amount or safety of this medication to Genentech, Inc., Genentech Accevely impact the patient's therapeutic on described herein. (e) The services ken until the patient consent docume quirements could result in outreach uracy of information submitted. (f) I ure acceptance of the country of the	polity criteria, ple esentative. In the property of the prope	ease speak to tes, administration: ing a Genentech product the authorization to red dispensing pharmac attempt to seek reimble alf of the patient, may increase must compratient meets the criter see not provide free dru	ct is not listed elease the y, or other ursement for free nclude benefits ly with all state- a for Genentecking in the instance
Dispense: 1-shipment supply. mg (mL) once daily 1-time refill. Weight-based dos Your signature authorizes the specialty phare Step 7 Health Ca By submitting this form, I certify: (a) The above therapy in the FDA-approved label, I am prescribing the medica information above and other protected health informati contractors for the purpose of requesting reimburseme product provided to the patient. I request Genentech Ac investigation (BI), prior authorization support (PA), co-p specific prescription requirements, such as e-prescribi Patient Foundation (GPF). (0) I understand that Genente	or 5 mg (6.6 mL) once daily ing will require a new Rx. macy to dispense needed ancillary supplies for enteral adr re Provider Certification vis medically necessary for this patient and the treatment decision tion for an "unapproved" use, meaning that the FDA has not appro on (as defined by the Health Insurance Portability and Accountab int support, assisting in initiating or continuing therapy, as a break cosess Solutions convey to the pharmacy chosen by the above-nam aya card and co-pay assistance foundation referral. (f) No action on ray, state-specific prescription form, fax language, etc. Noncomplich reserves the right to modify or discontinue the program at any	ministration of this med n has been made by the proved the efficacy, dosage ilitity Act of 1996 [HIPAA]) in treatment would negatined patient the prescription in these services will be ta iance with state-specific r time and to verify the acc	For full eligit Evrysdi reprodication, such as: ENFit® adapte rescribing physician. (b) If the indicat amount or safety of this medication to Genentech, Inc., Genentech Accevely impact the patient's therapeutic on described herein. (e) The services ken until the patient consent docume quirements could result in outreach uracy of information submitted. (f) I ure acceptance of the country of the	polity criteria, ple esentative. In the property of the prope	ease speak to tes, administration: ing a Genentech product the authorization to red dispensing pharmac attempt to seek reimble alf of the patient, may increase must compratient meets the criter see not provide free dru	ct is not listed elease the y, or other ursement for free nclude benefits ly with all state- a for Genentecking in the instance